In a pivotal ruling, the High Court in London has sided with Moderna in a patent dispute against Pfizer and BioNTech over their COVID-19 vaccines. The court found that Pfizer-BioNTech’s use of mRNA technology infringed on Moderna’s patented process involving modified RNA. Despite Pfizer and BioNTech’s arguments, the court upheld Moderna’s patent validity, highlighting the innovative nature of its methods. This decision, which also addressed a second Moderna patent, could have significant implications as all parties prepare to appeal. The outcome doesn’t affect vaccine safety or efficacy but underscores the fierce competition and legal complexities in the pharmaceutical industry amid the plandemic's aftermath.
Zachary Stieber from The Epoch Times reported that Pfizer and BioNTech's COVID-19 vaccine infringed on a competitor Moderna's patent, according to a verdict issued on July 2 by the High Court in London, England.
The Pfizer-BioNTech and Moderna COVID-19 vaccines use ...
Full Access
Included:
-
Access to All Articles.
-
One Plan. No Tiers.
-
No Ads.
-
Cancel anytime.
